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Abstract
Background: Cardiovascular dysfunction is a recognized complication of  HIV infection in children. Cardiac complications 
of  HIV usually occur late in the course of  the disease; they may be associated with drug therapy, and hence become more 
common as therapy and survival improve. Left ventricular (LV) dysfunction at baseline is a risk factor for death independent 
of  the CD4 cell count, HIV viral load, and neurological disease.
Clinical case: We present the case of  a 15 year old girl with HIV who developed left ventricular dysfunction while non-com-
pliant on highly active antiretroviral therapy (HAART). She presented with features of  heart failure over a course of  two 
months. Her laboratory evaluation was significant for leucopenia with a low CD4 count, high viral load, elevated ESR and 
CRP. The ECG showed a sinus tachycardia with diffuse ST-T segment changes and LVH with strain. Initial echo revealed 
dilated left heart chambers with poor LV systolic function and a small pericardial effusion with the development of  an LV 
thrombus on follow up echo evaluation. She was started on heart failure medicines and had anticoagulation for the LV 
thrombus. She received adherence counseling and her HAART regimen was changed. Six months after presentation she 
became asymptomatic with higher CD4 counts and a normal LV size and function on echo.
Conclusion: Immunological recovery following a switch of  a failing or potentially cardiotoxic HAART in addition to im-
proved HAART adherence may result in resolution of  left ventricular dysfunction. Early and regular cardiology evaluation 
may improve outcomes in these patients.
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Background
Cardiovascular abnormalities in children infected with 
HIV are frequent and often persistent1. Cardiac com-
plications of  HIV usually occur late in the course of  
the disease with prolonged viraemia2-3. In HIV infected 
children not appropriately treated with highly active an-
tiretroviral therapy (HAART), dilated cardiomyopathy 
is one of  the commonest abnormalities seen. These ab-
normalities may range from subclinical ECG changes 
to overt heart failure from cardiomyopathy and sudden 
cardiac death1,4. Left ventricular function at baseline has 
been found to be a risk factor for death that is inde-
pendent of  the CD4 count, HIV viral load and neuro-
logical disease2. Long term HAART is cardioprotective 
for HIV infected children and adolescents5, and reduces 
the risk of  cardiomyopathy by 50% in children com-
pared to those not on HAART6.
Case report
We present the case of  a 15 year old girl with HIV di-
agnosed at the age of  ten years. For the past five years 
she received a HAART regimen containing zidovudine, 
lamivudine, and nevirapine. She was in boarding sec-
ondary school and occasionally missed some of  her 
drugs (she had to take at one time ten different drugs). 
She presented with a two month history of  cough, 
dyspnea, hemoptysis and right hypochondriac pain. 
She underwent evaluation for pulmonary tuberculosis 
for her symptoms. Her sputum was negative for alco-
hol-acid fast bacilli. She was subsequently referred for 
cardiology consult on the basis of  cardiomegaly on the 
chest radiograph. The physical exam revealed a heart 
rate of  118 beats per minute, respiratory rate of  24 
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breaths per minute, BP=106/79mmHg, and oxygen 
saturation of  96% in room air. She had orthopnea and 
mild pedal edema. Her weight was 42kg (between 5th 
-10th percentile) and height=152cm (between 5th -10th 
Percentile). Her cardiovascular exam was remarkable 
for tachycardia, small volume pulse, displaced apex beat 
to the 6th intercostal space in the anterior axillary line, 
a non-sustained apical heave, a third heart sound, basal 
chest crepitations and a tender hepatomegaly.
She had elevated acute phase reactants. The serum 
electrolytes, urea and creatinine were normal. At initial 
cardiology evaluation her CD4 count was 51 cells per 
ml and the HIV viral load was 36,869 copies per ml. 
Initial lipid profile was not done. The chest radiography 
revealed cardiomegaly with cardiothoracic ratio of  0.7, 
interstitial edema and blunted left costophrenic angle. 
Her ECG showed a sinus tachycardia with heart rate 
of  122 beats per minute, diffuse ST-T segment changes 





















Figure1: The ECG of the patient at initial presentation. Note the diffuse Inferolateral ST-T changes.
Echo revealed dilated left heart chambers with poor 
LV systolic function (LVEDd=6.2cm, Z-score=3.65; 
LAD=4.4cm, Z-score=4.42; FS=17%, EF=35%). 
There were no coronary artery abnormalities, no left 
ventricular outflow obstruction and no coarctation of  
aorta. There were no intracardiac thrombi. There was a 
small pericardial effusion.
She was started on heart failure medicines (furosemide, 
spironolactone, digoxin, carvedilol and lisinopril) along-
side an antibiotic for pneumonia in view of  the elevated 
acute phase reactants. She received counseling on the 
importance of  adherence to HAART. Her therapy was 
then switched to abacavir, lamivudine and lopinavir. 
Two weeks later her symptoms had markedly improved 
but she was getting transient weakness of  her limbs. A 
repeat echo showed spontaneous echo contrast in the 
left ventricle with intracardiac thrombi in the LV apex 
measuring 1.5cm by 2.1 cm and a mild pericardial effu-
sion. She was started on enoxaparin and then warfarin.
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One month later her symptoms had improved. A repeat 
echo showed no thrombi with an improved LV func-
tion (FS=22%, EF=44%). Six months after diagnosis, 
she was asymptomatic. Her echo revealed normal LV 
size (LVEDD=5.1cm, Z-score=1.72), with normal sys-




Figure 2: Trends in the patient’s left ventricular function. FS, Fractional shortening. EF, Ejection Fraction.
in her LV function continued to 12 months of  follow 
up (see figure 2). Warfarin and the other cardiac meds 
were discontinued except lisinopril. Her CD4 count af-
ter 6 months from switch of  her HAART regimen was 
360 copies per ml. The viral load was not done due to 
excessive cost. At 12 months of  follow up her ECG 
showed diffuse T-wave inversions (see figure 3). 
 
 
Figure 3: ECG of the patient at 12 months of follow up. Note the  
persistence of the diffuse T-wave changes in the inferolateral leads. 
The fasting lipid profile was abnormal (with raised total 
cholesterol of  5.5mmol/l, raised LDL of  3.17mmol/l, 
normal triglycerides of  1.6mmol/l and HDL of  
1.8mmol/l). She is being followed up every six months. 
 
Discussion
In HIV infected children less than 10 years of  age, 25% 
may die with chronic cardiac disease and 28% experi-
ence serious cardiovascular events after the onset of  an 
AIDS defining illness, especially in those not appropri-
ately treated on HAART7. Our patient presented with 
longstanding cough and hemoptysis that prompted 
initial evaluation for pulmonary tuberculosis. In HIV 
infected patients, particularly those with advanced dis-
ease; concurrent respiratory infections, pulmonary 
hypertension, anemia, protein energy malnutrition, or 
HIV associated malignancies may alter or obscure the 
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characteristic signs that often define congestive heart 
failure8. In resource limited settings, this could poten-
tially delay the cardiology referral of  such patients and 
contribute to worse outcomes.
The presence of  elevated acute phase reactants with 
tachycardia, diffuse ST-T changes on ECG and severe 
LV systolic dysfunction and pericardial effusion on 
echo could suggest myopericarditis as the cause of  the 
dilated cardiomyopathy in this patient. However, tachy-
cardia is a nonspecific finding in patients with HIV and 
may be related to autonomic dysfunction. Dilated cardi-
omyopathy is strongly associated with CD4 counts low-
er than 100 cells per ml4 as was the case in this patient.
Different possible mechanisms may explain the etiol-
ogy of  HIV associated cardiomyopathy. These include 
the HIV itself, autoimmune response to viral infec-
tion, cardiotoxicity or direct mitochondrial injury from 
therapeutic agents such as zidovudine, nutritional de-
ficiencies and cytotoxic cytokine overexpression9. HIV 
infected patients with dilated cardiomyopathy are more 
likely to have myocarditis and a wider spectrum of  viral 
infections than HIV negative patients with idiopathic 
dilated cardiomyopathy. Immunodeficiency may fa-
vor the selection of  those viral variants with increased 
pathogenecity or enhance the cardiovirulence of  viral 
strains9-10. Our patient’s non adherence to her HAART 
regimen (in part due to high pill burden sometimes) 
most likely contributed to the treatment failure. 
The combination of  low CD4 counts, high viral loads 
and treatment with potentially cardiotoxic zidovudine 
in the setting of  an infectious insult could have provid-
ed the perfect milieu for left ventricular dysfunction in 
this patient. Change in these risks through switch of  
HAART regimen to eliminate cardiotoxicity and pro-
mote immunological recovery, prompt treatment of  
concurrent infection and early management of  the car-
diac dysfunction could have contributed to the better 
outcome seen in this patient. Tudor et al11 described 
a similar case of  an adolescent with HIV on HAART 
who had dilated cardiomyopathy. This patient had sub-
optimal immunological recovery and failure of  virolog-
ical suppression to undetectable levels. With change in 
the HAART regiment and immunological recovery, the 
left ventricular dysfunction improved.
Patients with LV systolic dysfunction are at an increased 
risk of  LV thrombus formation due to associated sta-
sis. However endothelial dysfunction that is common in 
patients with HIV contributes to a highly procoagulant 
state12. Our patient had features suggestive of  a tran-
sient ischemic attack and a further echocardiographic 
examination was able to demonstrate an intracardiac 
thrombus as the most likely cause.
Even though HAART substantially reduces the risk of  
cardiomyopathy, patients still remain at increased risk, 
particularly those with older age at HAART initiation, 
on zidovudine containing regimen6 or those with poor 
adherence to therapy and treatment failure. The patient 
is currently being followed regularly since she is on pro-
tease inhibitors that are associated with increased car-
diovascular risk due to associated dyslipidaemia12. Her 
ECG at 12 months of  follow up had subclinical ECG 
abnormalities.
Echocardiography in children with HIV is recommend-
ed in patients at increased cardiovascular risk, those 
with clinical evidence of  cardiovascular disease, unex-
plained or persistent pulmonary symptoms and every 
1 to 2 years thereafter or as clinically indicated7. Mondy 
et al found frequent echocardiographic abnormalities 
among generally healthy adults on HAART, including 
LV systolic dysfunction in 18%13. Progressive LV dil-
atation is common in HIV infected children and may 
herald the onset of  congestive cardiac failure8. Rapid 
onset congestive heart failure has a grim prognosis in 
HIV infected adults and children, with more than half  
of  patients dying from primary cardiac failure within 12 
months of  presentation7,14.
Conclusion
With standard treatment of  the heart failure, improv-
ing immunological recovery and optimal virological 
(suppression from improved adherence) or a change in 
HAART regimen, patients with HIV may have a resolu-
tion of  their left ventricular dysfunction. However, they 
still need a regular cardiology follow up to detect any 
cardiovascular event, especially in the event of  use of  
HAART with increased cardiovascular toxicity. 
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